AVDL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

80.30M

+59.29%

0.050

-266.6%

80.07M

+52.48%

0.183

-466.56%

89.54M

+31.42%

0.130

-360%

Estimates Revision

The market is revising Upward the revenue expectations for Avadel Pharmaceuticals plc (AVDL) for FY2025, with the revenue forecasts being adjusted by 2.01% over the past three months. During the same period, the stock price has changed by 53.57%.

Revenue Estimates for FY2025

Revise Upward

+2.01%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+37.88%

In Past 3 Month

Stock Price

Go Up

+53.57%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast AVDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVDL is 19.93 USD with a low forecast of 18.50 USD and a high forecast of 22.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

10 Hold

0 Sell

Hold

Current: 0.000

Low

18.50

Averages

19.93

High

22.50

Current: 0.000

Low

18.50

Averages

19.93

High

22.50

Wells Fargo

Equal Weight

maintain

$20

2025-11-20

Reason

Wells Fargo

Price Target

$20

2025-11-20

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $20 and keeps an Equal Weight rating on the shares. The firm says updated Alkermes' (ALKS) offer looks better to Wells, with a similar upfront but better CVR terms that it thinks are likely to pay out.

Truist

initiated

$50

2025-11-11

Reason

Truist

Price Target

$50

2025-11-11

initiated

Reason

Truist initiated coverage of Alkermes (ALKS) with a Buy rating and $50 price target. The firm values the base business and cash at about $29 per share, which it sees "setting a high floor" heading into Phase 2 Vibrance-2 data in narcolepsy type 2. Narcolepsy type 1 alone is worth $8 per share in the firm's sum-of-the-parts valuation, while NT2 and idiopathic hypersomnia contribute $8 per share and $5 per share, respectively, the analyst tells investors. Alkermes "doubling down" in sleep space with the acquisition of Avadel (AVDL) is a strategic move that gives it a first-mover advantage over Takeda (TAK), the analyst added.

UBS

Buy

Neutral

downgrade

$20

2025-10-28

Reason

UBS

Price Target

$20

2025-10-28

downgrade

Buy

Neutral

Reason

UBS downgraded Avadel Pharmaceuticals (AVDL) to Neutral from Buy with an unchanged price target of $20 after Alkermes (ALKS) announced an agreement to acquire Avadel for $18.50/share plus a contingent value right entitling shareholders to a $1.50 per share potential payment contingent on the FDA approval of Lumryz in idiopathic hypersomnia.

Morgan Stanley

Overweight

maintain

$180 -> $183

2025-10-24

Reason

Morgan Stanley

Price Target

$180 -> $183

2025-10-24

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Jazz Pharmaceuticals (JAZZ) to $183 from $180 and keeps an Overweight rating on the shares after the company announced a settlement of ongoing patent litigation with Avadel (AVDL) over high sodium oxybate Lumryz. The firm now includes royalty revenues from Lumryz in its estimates.

Deutsche Bank

David Hoang

Buy -> Hold

downgrade

$20

2025-10-23

Reason

Deutsche Bank

David Hoang

Price Target

$20

2025-10-23

downgrade

Buy -> Hold

Reason

Deutsche Bank analyst David Hoang downgraded Avadel Pharmaceuticals (AVDL) to Hold from Buy with a $20 price target after the company entered into a definitive agreement to be acquired by Alkermes (ALKS) in an all-cash transaction for up to $20.00 per share - $18.50 per share plus a contingent value right of $1.50 per share.

Piper Sandler

David Amsellem

Overweight

maintain

$38 -> $45

2025-10-23

Reason

Piper Sandler

David Amsellem

Price Target

$38 -> $45

2025-10-23

maintain

Overweight

Reason

Piper Sandler analyst David Amsellem raised the firm's price target on Alkermes (ALKS) to $45 from $38 and keeps an Overweight rating on the shares in the wake of the company's plans to acquire Avadel (AVDL). The firm surmises that the relatively muted market reaction to what is a significantly accretive transaction is likely a nod to the longer-term uncertainty associated with the Lumryz sales trajectory amid the eventual availability of multiple orexin 2 receptor agonists. That said, Piper envisions a sizable role for oxybate products in a world with OX2R agonists.

Valuation Metrics

The current forward P/E ratio for Avadel Pharmaceuticals PLC (AVDL.O) is 31.13, compared to its 5-year average forward P/E of 127.27. For a more detailed relative valuation and DCF analysis to assess Avadel Pharmaceuticals PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

127.27

Current PE

31.13

Overvalued PE

908.98

Undervalued PE

-654.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

22.92

Current EV/EBITDA

27.98

Overvalued EV/EBITDA

34.16

Undervalued EV/EBITDA

11.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.90

Current PS

6.14

Overvalued PS

6.47

Undervalued PS

3.33

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AVDL News & Events

Events Timeline

No data

News

8.5

01-09Globenewswire

PinnedState Street Increases Stake in Avadel Pharmaceuticals by 2.36%

4.0

01-08Globenewswire

State Street Increases Stake in Avadel Pharmaceuticals by 2.35%

5.0

01-07Globenewswire

State Street Increases Stake in Avadel Pharmaceuticals by 2.36%

People Also Watch

Frequently Asked Questions

What is Avadel Pharmaceuticals PLC (AVDL) stock price today?

The current price of AVDL is 21.5 USD — it has increased 0.09 % in the last trading day.

What is Avadel Pharmaceuticals PLC (AVDL)'s business?

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

What is the price predicton of AVDL Stock?

What is Avadel Pharmaceuticals PLC (AVDL)'s revenue for the last quarter?

Avadel Pharmaceuticals PLC revenue for the last quarter amounts to 77.47M USD, increased 54.86 % YoY.

What is Avadel Pharmaceuticals PLC (AVDL)'s earnings per share (EPS) for the last quarter?

Avadel Pharmaceuticals PLC. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Avadel Pharmaceuticals PLC (AVDL)'s fundamentals?

How many employees does Avadel Pharmaceuticals PLC (AVDL). have?

Avadel Pharmaceuticals PLC (AVDL) has 188 emplpoyees as of January 10 2026.

What is Avadel Pharmaceuticals PLC (AVDL) market cap?

Today AVDL has the market capitalization of 2.11B USD.